Cue Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cue Biopharma (CUE).

Price Target Range — 7 Quarters

Analyst Consensus — 8 Analysts

2S.Buy

6Buy

Consensus RatingBuy# Analysts8Avg. Consensus PT$127Upside to Avg. PT+490.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 18, 2026	B. Riley Securities	Mayank Mamtani	Initiate	Buy	$83
Aug 25, 2025	LUCID CAPITAL MARKETS	Dev Prasad	Initiate	Buy	$120
Apr 2, 2025	Citizens Capital Markets	Reni Benjamin	Maintained	Market Outperform	$60
Aug 20, 2024	Stifel	Stephen Willey	PT Cut	Buy	$240→$120
Jul 26, 2024	JMP Securities	Reni Benjamin	PT Cut	Market Outperform	$450→$60
Jul 26, 2024	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$240→$90
Apr 9, 2024	Stifel	Stephen Willey	Maintained	Buy	$240
Apr 9, 2024	Oppenheimer	Leland Gershell	Maintained	Outperform	$300
Apr 3, 2024	Piper Sandler	Edward Tenthoff	Maintained	Overweight	$240
Mar 13, 2024	Jefferies	Maury Raycroft	Initiate	Buy	$180
Nov 6, 2023	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$210→$240

Analyst Ratings News

This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Analysts initiated bullish coverage on TRAX, BGSI, NPCE, CUE and NGVC, assigning Outperform/Buy ratings with price targets from $18 to $120.

Avi Kapoor

PRO
B. Riley Securities Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $83

B. Riley Securities analyst Mayank Mamtani initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Buy rating and announces Price Target of $83.

Benzinga Newsdesk

PRO
LUCID CAPITAL MARKETS Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $4

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Buy rating and announces Price Target of $4.

Benzinga Newsdesk

PRO
Citizens Capital Markets Reiterates Market Outperform on Cue Biopharma, Maintains $2 Price Target

Citizens Capital Markets analyst Reni Benjamin reiterates Cue Biopharma (NASDAQ:CUE) with a Market Outperform and maintains $2 price target.

Benzinga Newsdesk

PRO
Stifel Maintains Buy on Cue Biopharma, Lowers Price Target to $4

Stifel analyst Stephen Willey maintains Cue Biopharma (NASDAQ:CUE) with a Buy and lowers the price target from $8 to $4.

Benzinga Newsdesk

Cue Biopharma, Inc. Reports Q2 Loss, Tops Revenue Estimates

Cue Biopharma, Inc. (NASDAQ: CUE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.

Zacks

Cue Biopharma Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Cue Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRO
B. Riley Securities Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $83

PRO
LUCID CAPITAL MARKETS Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $4

PRO
Citizens Capital Markets Reiterates Market Outperform on Cue Biopharma, Maintains $2 Price Target

PRO
Stifel Maintains Buy on Cue Biopharma, Lowers Price Target to $4

Cue Biopharma, Inc. Reports Q2 Loss, Tops Revenue Estimates

People Also Watch

People Also Watch

Cue Biopharma Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Cue Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PROB. Riley Securities Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $83

PROLUCID CAPITAL MARKETS Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $4

PROCitizens Capital Markets Reiterates Market Outperform on Cue Biopharma, Maintains $2 Price Target

PROStifel Maintains Buy on Cue Biopharma, Lowers Price Target to $4

Cue Biopharma, Inc. Reports Q2 Loss, Tops Revenue Estimates

People Also Watch

People Also Watch

PRO
B. Riley Securities Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $83

PRO
LUCID CAPITAL MARKETS Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $4

PRO
Citizens Capital Markets Reiterates Market Outperform on Cue Biopharma, Maintains $2 Price Target

PRO
Stifel Maintains Buy on Cue Biopharma, Lowers Price Target to $4